FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. Medicine (Baltimore). 2018 Sep;97(38):e12414. doi: ...

Repetitive transcranial magnetic stimulation offers rapid depression relief for patients unresponsive to conventional ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

A McMaster University researcher credited for discovering a chemical compound with “huge potential” in treating brain health ...

University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into ...

"Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program ... ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

Depression and anxiety rank among the top global health challenges. Since 1990, these disorders have surged, placing them in ...

But this year, the U.S. Food and Drug Administration cleared the first app-based treatment for major ... While the idea of using an app to treat depression is still new, mental-health professionals ...

Genetic testing examines a person’s DNA to identify specific genes or variants that influence how they may respond to ...